Matthew E. Brown

This study generates hypoimmunogenic gastric insulin-secreting organoids (GINS) and shows PD-L1 engineering improves their survival under immune challenge.

This study shows that human stem cell-derived β-cells expressing a high-affinity CD155 variant reduce immune cell cytotoxicity, improving their potential for type 1 diabetes therapy.

This study shows that ImmTAAI, a beta cell-targeted PD-1 agonist, inhibits T cell activity in human type 1 diabetes by increasing T cell motility and reducing cytokine secretion.

This study shows that blocking CD226 reduces diabetes in NOD mice by enhancing Treg function and reducing effector T cell activity.